News & Observer readers comments on NC's business ranking, speeding in a Raleigh area, a gun bill, flooding, Thom Tillis, ...

Sanofi and Regeneron, AstraZeneca, Roche’s Genentech and GSK have provided support for the Living Well with COPD educational ...

Patients with neuro conditions are asked to consult with their neurologist, above all else, before seeking out therapeutic ...

Half of the year is over! So, which pharmaceutical giant outpaces the others? Sharp investors wonder whose market ...

The story behind the development of immune checkpoint inhibitors, fulfilling the promise of cancer immunotherapy ...

Analytical chemistry researchers at the University of Amsterdam's Van 't Hoff Institute for Molecular Sciences (HIMS) have ...

Genentech halts an ulcerative colitis trial for vixarelimab but continues testing it for lung-scarring diseases, using AI for target selection.

Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial.

Genentech's Lunsumio+Polivy combo reduces disease progression risk by 59% in relapsed large B-cell lymphoma. Read more here.

Genentech’s lymphoma portfolio is one of the broadest in the industry, providing a unique and much-needed opportunity to combine regimens with different and complementary mechanisms of action.